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Steven J WangAbstract
The increasing proportion of human papilloma virus-related oropharynx cancers has led to improved success in the
treatment of this disease. However, the current low recurrence rate after treatment of oropharyngeal cancer highlights
the continued need for, as well as the challenges of, designing an effective follow-up surveillance program. There are
frequently multiple modalities used in the treatment of oropharyngeal cancer, resulting in short- and long-term tissue
changes to the head and neck that challenge clinical distinction of recurrence versus treatment-related changes. The
oropharynx subsite is characterized by complex anatomy not always accessible to physical exam, making radiologic
imaging a potentially useful supplement for effective follow-up assessment. In this manuscript, the literature regarding
the type of radiologic imaging modality and the frequency of obtaining imaging studies in the surveillance follow-up
after treatment of oropharyngeal cancer is reviewed. While ultrasound and MRI have useful characteristics that deserve
further study, PET/CT appears to have the best sensitivity and specificity for imaging surveillance follow-up of head and
neck cancers including oropharyngeal cancer. A negative PET/CT is particularly useful as a predictor of prognosis and
can guide the clinician as to when to stop obtaining additional imaging studies in the absence of clinical signs of
recurrence. However, there is scant evidence that imaging surveillance can improve survival outcomes. Suggestions to
guide future imaging surveillance research studies are provided.
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Treatment of oropharyngeal cancer includes the fre-
quent use of organ-preservation chemoradiation proto-
cols. Reports in the literature have shown high success
with this approach, with advanced stage III/IV oropha-
ryngeal cancers having >80% 2- and 5-year disease-free
survival rates [1,2]. More recently, primary surgery with
emphasis on transoral approaches for early T-stage oro-
pharyngeal cancer has become more common, with
similarly favorable results [3]. Nonetheless, some oro-
pharyngeal cancer patients do suffer recurrent disease,
emphasizing the need for post-treatment surveillance.
The exact benefit of a surveillance program, the type of
surveillance program, and the interval and duration of a
surveillance program remain undefined. Because the
oropharynx can be a difficult anatomic location to evalu-
ate, and this evaluation may be further obscured by
treatment-related tissue changes, it has been generallyCorrespondence: swang@ohns.ucsf.edu
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unless otherwise stated.considered that physical examination alone is insufficient
as a surveillance method for oropharyngeal cancer.
Thus, radiologic imaging studies, in addition to the
physical exam, have been commonly employed in cancer
surveillance for this disease. The purpose of this manu-
script is to review the evidence regarding the role of
radiologic imaging for surveillance after treatment of
oropharyngeal cancer.
The goal of a head and neck cancer surveillance pro-
gram is to achieve earlier detection of recurrent cancer
compared to patient self-identification through frequent,
interval clinical assessment. To be beneficial, earlier de-
tection should increase the likelihood of successful sal-
vage therapy. However, there is limited data with regard
to the benefits for any head and neck cancer surveillance
program. The increased survival of patients with recur-
rent tumors diagnosed by routine surveillance reported
in some studies have been criticized as being due, in
part, to lead time bias (that is, early diagnosis falsely ap-
pears to prolong survival) [4]. Agrawal et al. found that
the majority of patients diagnosed with recurrent headan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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findings prior to routine surveillance office follow-up
[5]. In a subsequent study, survival in the recurrent dis-
ease setting appeared to be more dependent on variables
such as prior early disease stage and recurrence location
(local-only rather than regional or distant) than those as-
sociated with follow-up surveillance [6]. There is no
doubt that some head and neck cancer patients with re-
currence achieve improved disease outcome through
identification in an earlier subclinical point in time.
However, the current state of scientific evidence in the
literature is scant on this issue, highlighting the need for
more critical assessments of head and neck cancer sur-
veillance recommendations.
The proper assessment of any cancer surveillance program
must consider 1) the recurrence rate, 2) the optimal method
for surveillance, and 3) whether earlier detection of recur-
rence leads to increased rates of successful salvage treatment
and improved survival. Currently, in North America, patients
with oropharynx cancers, whether treated with chemoradia-
tion or with primary surgery +/− adjuvant therapy, have a
low recurrence rate compared to historic data [7]. Recently,
Garden et al. reported a 5-year overall recurrence rate of
18% following IMRT treatment of oropharyngeal cancer [2].
The rise in human papilloma virus (HPV)-related orophar-
ynx cancers in many parts of the world is a key factor in the
recently reported improved treatment results. Ang et al.
found that HPV-positive oropharyngeal cancer patients had
up to twofold greater 5-year overall survival and less than
half the recurrence rate of HPV-negative oropharyngeal can-
cer patients of the same stage [8]. Because of the decreased
incidence of smoking, the incidence of tobacco-related oro-
pharyngeal cancer in the USA has declined by 50% while
HPV-positive oropharyngeal cancer cases have increased by
225% since 1988, with HPV-positive cancers now comprising
the majority of oropharyngeal cancers that occur in the USA
today [9]. The low recurrence rate associated with these tu-
mors means that any surveillance program to be of meaning-
ful benefit must have high sensitivity, in order to successfully
identify the relatively few recurrences, as well as high specifi-
city, to avoid unnecessary additional testing, intervention,
and anxiety since the likelihood of actually having a recur-
rence is low.
A second consideration for a cancer surveillance program
is the selection of the method for surveillance. Lacking any
serum tumor marker or other diagnostic test for recurrence,
most efforts have focused on radiologic imaging as the pri-
mary tool for head and neck cancer surveillance. It has been
reported that radiologic imaging adds to the sensitivity of
physical exam alone [10]. However, there is presently no con-
sensus regarding the optimal type of imaging surveillance
and the recommended frequency of any imaging sur-
veillance program. The current National Comprehen-
sive Cancer Network (NCCN) guidelines recommend abaseline cross-sectional imaging study at 4 to 6 months
following treatment of oropharynx cancer, but there are
no recommendations for subsequent routine follow-up
imaging [11]. Nonetheless, frequent and expensive im-
aging studies are routinely obtained at many head and
neck cancer treatment centers. In contrast, other centers
take a more individualized approach, with post-treatment
imaging limited to when a recurrent tumor is suspected,
in order to confirm the presence of such a lesion and to
determine its extent. The type of imaging study obtained
also varies from center to center and may include CT,
MRI, PET/CT, or ultrasound. Most recent studies of head
and neck cancer surveillance have focused on PET/CT.
Below, the literature on the utility of the various modal-
ities of post-treatment imaging surveillance for head and
neck cancer, generally, and oropharynx cancer, specifically,
is reviewed.
Ultrasound for surveillance
Ultrasound as a surveillance tool has the advantage of
lower cost and the capability for use in conjunction with
the routine clinical visit and exam. A previous report from
our institution comparing ultrasound and PET/CT for sta-
ging and surveillance of head and neck and thyroid cancer
found superior sensitivity (96.8% vs. 90.3%), specificity
(93.3% vs. 20%), positive predictive value (96% vs. 70%),
and negative predictive value (93% vs. 50%) for ultrasound
compared to PET/CT [12]. Another similar study compar-
ing ultrasound with PET/CT found that the two tech-
niques had equivalent accuracy for surveillance of head
and neck cancer, and the authors concluded that ultra-
sound could be considered complementary to PET/CT for
detecting subclinical regional recurrences after head and
neck cancer treatment [13]. On the other hand, the use of
ultrasound as a practical tool for head and neck cancer
surveillance is still relatively constrained due to the limited
number of practitioners who are skilled in head and neck
ultrasonography.
MRI for surveillance
MRI is used for head and neck cancer surveillance in
many centers. Compared to CT or PET/CT, MRI can pro-
vide superior anatomic delineation, particularly with re-
gard to lesions near the skull base. It may also be the more
useful study if one desires to confirm and assess the extent
of a suspected recurrence, so that surgical planning can be
done. We previously reported results of 43 patients treated
for oropharynx cancer who underwent 252 head and neck
MRI scans [14]. In this study, two recurrences were identi-
fied on MRI in otherwise asymptomatic patients while
routine clinical follow-up and physical examination identi-
fied an additional two recurrences. Six patients experi-
enced false-positive surveillance scans that resulted in
intervention. Salvage treatment was performed in the two
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whom remains free of disease at follow-up. The overall
sensitivity and specificity of the MRI surveillance program
was 50% and 83%, respectively, suggesting that MRI may
have limited utility as a surveillance method for orophar-
ynx cancers in otherwise asymptomatic patients. The use
of diffusion-weighted MRI may increase the sensitivity for
persistent or recurrent head and neck cancer. Vandeca-
veye and colleagues reported diffusion-weighted MRI to
have a sensitivity of 94.6%, specificity of 95.9%, and overall
accuracy of 95.5% for the detection of clinically suspected
persistent or recurrent head and neck cancer [15].
PET/CT for surveillance
Studies examining the role of PET in head and neck cancer
surveillance have found notable benefits in the initial post-
treatment period. Krabbe et al. compared PET versus regu-
lar clinical follow-up for oral cavity and oropharyngeal car-
cinoma [16]. PET was significantly more sensitive than
regular follow-up for identification of recurrence. The
benefit of PET was highest for the 3- and 6-month post-
treatment scan. Kao et al. studied 80 head and neck cancer
patients who underwent 240 post-treatment scans at 4- to
6-month intervals over an approximately 3-year period
[17]. In their study, the sensitivity was 92%, the specificity
82%, the positive predictive value 42%, and the negative
predictive value 98% for detecting locoregional recur-
rences. A negative versus positive PET/CT within 6 months
of completion of treatment offered a significant prognostic
value (3-year overall survival 100% vs. 32%, P = 0.01). These
authors concluded that PET/CT is a sensitive technique
for the detection of recurrent head and neck cancer.
Abgral et al. examined the benefit of a single 12-
month post-treatment PET/CT scan in 91 patients with-
out clinical evidence of head and neck cancer recurrence
[18]. Fifty-two PET/CTs were reported negative and 39
reported positive. The sensitivity was 100%, specificity
85%, negative predictive value 100%, and positive pre-
dictive value 77%. These authors concluded that there is
benefit to doing a PET/CT at 12 months after treatment
for asymptomatic patients. Manikantan et al. also sug-
gested that a PET/CT at 12 months may be useful, but
that further studies are required to confirm this recom-
mendation [19]. These authors also recommended the
use of ultrasound +/− fine-needle aspiration biopsy for
follow-up of necks that have not had surgery.
A meta-analysis of 27 manuscripts on the utility of
PET scans for the post-treatment follow-up of head and
neck cancer was done by Isles and colleagues [20]. While
this meta-analysis mostly included studies that examined
the utility of PET for the initial evaluation of chemoradi-
ation treatment response, their analysis showed an over-
all pooled sensitivity of 94% for the detection of residual
or recurrent disease at the primary site, with a sensitivityof 74% for residual or recurrent neck disease. The nega-
tive predictive values were 95% for the primary site and
96% for neck disease, whereas the positive predictive
values were 75% for the primary site and 49% for the
neck.
McDermott et al. considered the negative predictive
value of surveillance PET/CT in head and neck cancer
[21]. That is, does a negative PET/CT reduce the need
for further imaging surveillance. Their study involved
512 patients (31% oropharynx, 31% oral cavity, 19% lar-
ynx or hypopharynx, 8% unknown primary). They re-
ported that a single negative PET/CT (214 patients)
carries a negative predictive value of 91%, which they
considered not adequate to defer further radiologic sur-
veillance. However, two consecutive negative PET/CTs
within 6 months (114 patients) carry a 98% negative pre-
dictive value, which could obviate further radiologic im-
aging in the absence of clinical signs of recurrence.
In North America and some other areas of the world,
HPV-related oropharynx cancers are increasingly preva-
lent, with a better associated prognosis and response to
treatment [8,9]. Zhang et al. examined whether HPV sta-
tus could augment the predictive utility of PET/CT inter-
pretation in the post-treatment setting [22]. These authors
found that in HPV-positive patients, a negative first post-
treatment PET/CT is highly predictive of disease-free sur-
vival but not in HPV-negative patients. In a follow-up
study from this same group, 61 oropharynx cancer pa-
tients were analyzed of which 50 (82%) tumors were HPV-
positive [23]. The negative predictive value of a negative
initial post-treatment PET/CT for HPV-positive orophar-
ynx cancer patients was 93% versus 85% for the orophar-
ynx cancer group overall. On multivariate analysis, HPV
status and negative initial PET/CT were the only signifi-
cant predictors of recurrence.
It also appears that the technique of PET/CT is relevant
in the utility of the imaging surveillance program. In many
centers, the CT component of the combined PET study is
with a non-contrast, low-definition technique whose intent
is for anatomic correlation of the PET findings only. How-
ever, Rangaswamy et al. observed an improvement in the
detection of locoregional recurrence in head and neck
malignancies when F-18 FDG PET is combined with
high-resolution contrast-enhanced CT [24]. Their study
compared PET/low-definition CT versus PET/high-reso-
lution contrast-enhanced CT versus physical exam with
in-office endoscopy. They found that PET/high-resolution
contrast-enhanced CT had superior sensitivity and nega-
tive predictive value. They further reported that the find-
ings of the positive PET/CT had an impact on treatment
for 9 of the 103 patients in the study.
A final consideration of a cancer surveillance program is
whether the earlier detection of subclinical, asymptomatic
recurrences leads to improved salvage outcomes. While
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that earlier detection of recurrence in oropharynx cancer
does increase the opportunity for treatment cure, the evi-
dence in the reported literature is less clear. The likelihood
of salvage treatment success depends heavily on the site of
recurrence, with local and/or regional recurrences more
likely to be salvaged than distant recurrences.
Ho et al. studied the impact of PET/CT surveillance for
detecting head and neck cancer recurrence at 12 and
24 months post-treatment [25]. In a 10-year retrospective
analysis of 284 treated head and neck cancer patients (49%
oropharynx, 19% oral cavity, 18% nasopharynx, 8% larynx/
hypopharynx, 6% unknown primary), these authors reviewed
175 patients with 3- and 12-month scans and 77 with 3-, 12-
, and 24-month scans. The PET/CT detection rate of occult
recurrence was 9% at 12 months and 4% at 24 months.
There was no difference in 3-year disease-free survival and
overall survival for PET/CT detected versus clinically de-
tected recurrences. These authors concluded that PET/CT
offers uncertain benefit to those with initial 3-month negative
PET/CT, although it was acknowledged that larger prospect-
ive studies are needed to fully answer this question.
Similarly, Dunsky et al. suggested that PET/CT could
be an effective surveillance tool for early detection of
asymptomatic disease in patients treated for head and
neck cancer; however, the outcomes of those patients
with identified recurrences remained poor [26]. Their
study reported the detection of asymptomatic lesions in
24 of 103 (20%) patients; among the 24 identified recur-
rences, 20 (82%) of these were distant metastases and 4
(18%) were in locoregional sites.
A difficulty in drawing conclusions from the published lit-
erature is the inconsistency in the design and analysis of im-
aging surveillance studies. Patel et al. recently carried out a
systematic review of the evidence for use of PET/CT in theTable 1 Surveillance radiologic imaging after oropharynx can
Imaging modality Reference (year)
Ultrasound Hwang et al. (2009) [12]; Wierzbicka et a
of head/neck and thyroid cancer
MRI Kangelaris et al. (2010) [14]: MRI for surve
Vandecaveye et al. (2007) [15]: diffusion-
PET Krabbe et al. (2009) [16]; Kao et al. (2009
PET/CT for recurrent head and neck can
Isles et al. (2008) [20]: systematic review
McDermott et al. (2013) [21]: negative pr
Zhang et al. (2011) [22]; Koshkareva et al
Ho et al. (2013) [25]; Dunsky et al. (2013)
surveillance program
Future directions in surveillance
imaging
Lee et al. (2014) [28]: PET/MRI for head/n
Bogdanov and Mazzanti (2011) [29]; Yan
agents and tumor biomarkers for MR im
Differding et al. (2015) [32]; Servagi-Vernpost-treatment surveillance follow-up setting for head and
neck cancers [27]. These authors found only four head and
neck studies which they believed met adequate criteria for
quality and that included specific data for long-term follow-
up imaging surveillance without pooling data with the initial
post-treatment evaluation. For these four studies, there was a
pooled sensitivity of 75% to 100%, specificity of 92% to 95%,
positive predictive value of 50% to 90%, and negative predict-
ive value of 100%. These authors concluded that there is a
lack of evidence supporting PET/CT for post-treatment sur-
veillance of head and neck cancers beyond its use in
the initial post-treatment evaluation. Standardization
of methods of imaging surveillance and emphasis on
the importance of conducting prospective multi-institutional
studies was recommended.
Future directions in surveillance radiologic imaging
There are several methods for radiologic imaging which offer
the promise of improved detection of cancer recurrence but
have not yet found widespread application for oropharyngeal
carcinoma [28-32]. The use of integrated PET/MRI for the
evaluation of head and neck cancer has been described [28].
PET/MRI has theoretical advantages over PET/CT due to
the superior soft-tissue delineation of malignancies with MRI
compared to contrast-enhanced CT and the absence of radi-
ation dose with MRI. Drawbacks with whole-body PET/MRI
include motion artifact of solid organ evaluation (lung, liver/
abdomen) associated with respiration, which is greater with
MRI than with CT, and the prolonged imaging time (typic-
ally, in excess of 1 h) of PET/MRI which may be difficult for
some patients to tolerate.
Other strategies to improve cancer detection with
radiologic imaging include the use of different contrast
agents or probes to increase the imaging sensitivity for
tumors [29-32]. To date, the most common contrastcer treatment
l. (2011) [13]: comparison of US versus PET/CT for staging and surveillance
illance after chemoradiation treatment of oropharynx cancer
weighted MRI for head/neck cancer after chemoradiation
) [17]; Abgral et al. (2009) [18]; Manikantan et al. (2009) [19]: sensitivity of
cer
of PET for follow-up of head/neck cancer after radiation
edictive value of PET/CT for head/neck surveillance
. (2014) [23]: PET/CT for surveillance of HPV+ oropharynx cancer
[26]; Patel et al. (2013) [27]: lack of survival benefit for routine PET/CT
eck cancer
keelov et al. (2011) [30]; Glunde and Bhujwalla (2011) [31]: newer contrast
aging
at et al. (2014) [33]: PET imaging biomarkers in head and neck cancer
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Newer MR contrast agents are being developed with
molecular specificities that can produce signal changes
when these agents bind to cell surface receptors on
tumor cells or extracellular matrix components [29].
These novel cancer-specific contrast agents with en-
hanced magnetic properties offer the potential to in-
crease the sensitivity of the MR imaging technique for
tumor identification. Tumor-specific contrast agents
provide the clinician with molecular imaging informa-
tion that can facilitate cancer diagnosis, monitoring of
chemotherapeutic drug delivery, and assessment of the
overall response to treatment [30,31].
The use of newer molecular probes other than
18F-fluorodeoxyglucose (18F-FDG) for PET imaging
has also been reported [32]. 18F-fluoromethyltyrosine
(18F-FMT) has lower sensitivity for head and neck
cancer compared to 18F-FDG; however, 18F-FMT ap-
pears to be more tumor-specific than 18F-FDG as
there is no uptake of this tracer with inflammation,
a property which could aid in the identification of persistent
regional nodal metastatic disease [32]. The specific hypoxia
tracer 18F-fluoroazomycin arabinoside (18F-FAZA) has
been described as a method for PET identification of head
and neck cancers with the property of greater tumor hyp-
oxia, which in the future could help individualize treatment,
for instance, by selecting patients for hypoxia sensitizers or
special intensified radiation treatment techniques [33].
Other PET tracers are being developed that can provide
better characterization of the tumor microenvironment,
proliferation potential, and tumor metabolism, which may
aid in the early diagnosis of cancer recurrence [32].
A summary of current and future imaging strategies
for the detection of recurrent oropharynx carcinoma,
with references, is shown in Table 1.
Conclusions
In summary, there is no high-level scientific evidence
to guide us to the optimal strategy of radiologic im-
aging surveillance for patients treated for oropharynx
cancer. However, based on mostly retrospective and
single-institution case series reports as well as con-
sidering mainly studies that reported imaging surveil-
lance results across all head and neck cancer tumor
subsites, PET/CT appears the most sensitive and spe-
cific imaging modality for surveillance follow-up of
treated oropharynx cancer. PET/CT scans obtained
between 3 and 6 months after completion of treat-
ment and at 12 months post-treatment have notable
implications for prognosis. PET/CT has important clinical
utility because of a generally high specificity and negative
predictive value. If two consecutive negative PET/CT stud-
ies are obtained within an interval between 3 and
6 months, the likelihood of future recurrence is extremelylow. HPV status may further enhance the predictive reli-
ability of the PET/CT findings. However, additional studies
are needed to quantify the clinical outcome benefits of an
imaging surveillance program and to determine the most
appropriate duration and frequency of obtaining imaging
studies in this patient population.
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